news
Press release
 
July 18, 2013
First Robotic-Assisted Stent Placement in Acute Heart-Attack Patient Performed at Sanford Aberdeen Medical Center

Interventional Cardiologist performs CorPath® Robotic Angioplasty, door-to-balloon time superior to national average

Waltham, MA – July 18, 2013 – Corindus Vascular Robotics announced today that Sanford Aberdeen Medical Center in Aberdeen, S.D. became the first hospital to perform a Robotic Angioplasty for a patient with an acute heart-attack, achieving a far better door-to-balloon time than the national standard. The percutaneous coronary intervention (PCI) was performed by interventional cardiologist Dr. Puneet Sharma, to treat a patient that had experienced a heart-attack and presented to the Sanford Aberdeen emergency department. Utilizing the FDA-cleared CorPath System, Dr. Sharma was able to perform the robotic-assisted angioplasty procedure and restore blood flow to the patient’s heart within 68 minutes of their arrival.

The current nationwide standard for door-to-balloon time—from when a patient with a heart attack is presented to the emergency department (ED) to inflating a balloon in his coronary arteries to restore blood flow to the heart—is 90 minutes. These standards were developed by the American College of Cardiology (ACC) to improve timely access to the cath lab and by that improving clinical outcome.

“Timely access to emergency cardiac care and survival is partly dependent on access to services and technology,” said Dr. Sharma. “Being able to perform a CorPath Robotic Angioplasty on a STEMI patient within 68 minutes is a great benefit. As shown with the latest procedure, robotic-assisted angioplasties improve rural access and quality of care as more patients in this area will have access for advanced specialty care. The implementation of the CorPath System and its ability to precisely and rapidly execute an angioplasty procedure with only one stent in the patient heart is a great example of Sanford Health’s commitment to enhanced clinical outcome for our patients.”

The CorPath System is the first and only FDA cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Seated in an interventional cockpit, the interventional cardiologist advances stents and guidewires via a joy stick with millimeter by millimeter precision. The System, which is quickly being adopted as the new standard of care in coronary angioplasty procedures, may also improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

“The ability to improve door-to-balloon times demonstrates the maturity of CorPath Robotic Angioplasty,” said David Handler, president and chief executive officer of Corindus Vascular Robotics. “We designed the System to be very intuitive and user-friendly. As a result, the learning curve is minimal, allowing rural sites with less volume to implement CorPath Robotic Angioplasty into their practice with great clinical results.”

Sanford Health performs robotic-assisted angioplasty procedures with the CorPath System at both Sanford Heart Hospital in Sioux Falls and Sanford Aberdeen Medical Center. It is the first and only health system in the region utilizing the CorPath System.

The CorPath System is currently installed in leading medical centers across the United States.

About Sanford Aberdeen

The Sanford Aberdeen Medical Center is a new state-of-the-art hospital which opened in 2012 to meet the growing health care needs of the Aberdeen region and area communities. The 48-bed medical center is directly attached to the established multi-specialty Sanford Aberdeen Clinic. Sanford Aberdeen Medical Center is a full service regional hospital that includes adult and pediatric care, emergency/trauma, labor and delivery, critical care, cardiac cath lab, inpatient and outpatient surgical and procedural areas, inpatient and outpatient therapies.

For more information, please visit sanfordaberdeen.org.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window